Our Focus
We are a clinical-stage liver therapeutics biotechnology company pioneering a new class of medicines designed to bring safe and efficacious treatments for fibrosis, inflammation, and cancer to patients.
Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 12 years of research into galectin and fibrosis modulators. By employing our world-leading expertise in galectin and lysyl oxidase-like 2 (LOXL2) biology, we have developed our product candidates to modulate central disease pathways simultaneously and work synergistically with and enhance the efficacy of other therapeutics.
Our mission is to extend the healthy lifespan of patients by providing easily administered, highly efficacious, and well-tolerated treatments that enable long-term use and significantly improve quality of life.
